KOSDAQBiotech & Pharma140410

Mezzion Pharma

₩64,700▲ 1.41%2026-11-18 close
Market Cap
₩2T
Turnover
₩6.6B
Volume
100K
Shares out.
30.9M
PER
—
PBR
42.5×
EPS
-₩985
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Mezzion: A Loss-Making Biotech Awaiting Its Single-Asset Phase 3 Readout

Mezzion Pharma's valuation rests mainly on one drug, udenafil, while its filed results show operating losses every year from 2022 to 2025 and revenue rising for two straight quarters through Q3 2026.

  1. 1

    On a filed basis, revenue peaked at KRW 31.7 billion in 2023 and then fell to KRW 8.61 billion in 2024 and KRW 7.91 billion in 2025.

  2. 2

    The 2025 operating loss widened to KRW 16.8 billion, and the net loss attributable to controlling shareholders widened to KRW 34.9 billion, both larger than in 2024.

  3. 3

    Q3 2026 revenue rose 9.9% from the prior quarter to KRW 2.42 billion, yet an operating loss of KRW 4.21 billion continued.

  4. 4

    Total equity fell to KRW 17.2 billion at end-2025 and the debt ratio rose to 470.1%, a sharp narrowing of the balance-sheet cushion.

  5. 5

    The FUEL-2 Phase 3 readout is the largest variable for the company's valuation, and press reports have pointed to a possible announcement around late 2026.

02

Business structure

Mezzion Pharma was formerly known as Donga Pharm and adopted its current name in 2013, after which it concentrated on new drug development.

Its business started in erectile dysfunction and benign prostatic hyperplasia treatments, but it now focuses on rare cardiovascular drugs for patients with single-ventricle heart defects.

The lead pipeline asset, udenafil, was developed as an erectile dysfunction compound but has been repositioned as a treatment to prolong survival in patients with a single functional ventricle who have undergone Fontan surgery.

The FUEL-2 trial is a global Phase 3 study of 436 Fontan patients, and as of 2025 press reports it was running at 33 sites in the United States and 3 in Korea.

The first Phase 3 trial, FUEL-1, failed to reach statistical significance because it included many super-Fontan patients, and FUEL-2 was designed to exclude that group from the start. The company said it agreed with the FDA on a p-value threshold of 0.1 or below for approval.

In March 2022 the FDA did not grant approval over statistical significance concerns, and the company then pursued a repeat trial. With KRW 7.91 billion in 2025 revenue, the business is small, so operating losses appear to depend more on fixed-type development costs than on sales. The company is also preparing to enter the European market.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.1B-₩4.7B−218.6%
2025Q4₩2.1B-₩5.1B−242.3%
2026Q1₩2B-₩4.6B−226.4%
2026Q2₩2.2B-₩4.5B−206.3%
2026Q3₩2.4B-₩4.2B−174.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩30.7B-₩23.3B-₩36.3B−75.9%−138.3%105.9%
2023₩31.7B-₩14.5B-₩12.7B−45.7%−20.7%50.0%
2024₩8.6B-₩14.3B-₩19.5B−166.0%−42.3%60.6%
2025₩7.9B-₩16.8B-₩34.9B−212.0%−203.1%470.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a filed basis, annual revenue rose from KRW 30.7 billion in 2022 to KRW 31.7 billion in 2023, a 3.2% increase and the peak year, before falling 72.9% to KRW 8.61 billion in 2024 and 8.2% to KRW 7.91 billion in 2025, a second straight annual decline.

The largest year in the 2022 to 2025 window was 2023, and the smallest was 2025. Operating losses were KRW 23.3 billion in 2022, KRW 14.5 billion in 2023, KRW 14.3 billion in 2024 and KRW 16.8 billion in 2025, making four consecutive years of operating losses.

The operating margin improved from -75.9% in 2022 to -45.7% in 2023 but deteriorated to -166.0% in 2024 and -212.0% in 2025. The key feature is that operating losses did not shrink much while revenue collapsed, which pushed the ratio sharply lower.

The net loss attributable to controlling shareholders narrowed from KRW 36.3 billion in 2022 to KRW 12.7 billion in 2023 before widening to KRW 19.5 billion in 2024 and KRW 34.9 billion in 2025. Net income including non-controlling interests is reported at the same amounts in each year.

Operating cash outflows were KRW 12.1 billion, KRW 11 billion, KRW 18.5 billion and KRW 16.6 billion from 2022 to 2025. Total equity at end-2025 was KRW 17.2 billion against total liabilities of KRW 80.8 billion, and the debt ratio rose to 470.1% from 60.6% in 2024.

The Korea Exchange designated the company as an investment caution stock on March 17, 2026, citing operating losses in five consecutive business years.

Quarterly revenue fell from KRW 2.13 billion in Q3 2025 to KRW 2.02 billion in Q1 2026, then rose to KRW 2.2 billion in Q2 and KRW 2.42 billion in Q3 2026, two consecutive quarterly gains.

Operating losses narrowed from KRW 4.65 billion in Q3 2025 and KRW 5.05 billion in Q4 2025 to KRW 4.56 billion, KRW 4.54 billion and KRW 4.21 billion across Q1 to Q3 2026.

Net income attributable to controlling shareholders swung to a loss of KRW 24.6 billion in Q4 2025, then turned to a KRW 7.69 billion profit in Q2 2026 before returning to a KRW 7.45 billion loss in Q3 2026.

The Q2 2026 profit arose while operating losses continued, which points to non-operating items, and their details need to be checked in the periodic reports. The combined net loss attributable to controlling shareholders over the last four quarters was KRW 29.7 billion.

05

Industry analysis

Mezzion's end market is patients who have undergone Fontan surgery for single-ventricle heart defects, a rare-disease segment with limited treatment options. Press reports cite an analyst estimate of roughly 25,000 US patients aged 12 and older.

Real-world data is also accumulating: the company said in early 2026 that more than 4,000 patients and over 13,000 medical records had been recorded, and it expected many Fontan patients to be listed under the ICD-10 code by the end of 2026.

When it applied for approval in 2020, the company described its target as a market without competing products for pediatric and adolescent patients. Because few therapies have reached approval in this niche, regulatory standards for each trial remain a key variable for the sector.

In terms of cycle position, Mezzion is still pre-commercial. Compared with peers such as SK biopharmaceuticals, Alteogen and Yuhan, which have product sales as a revenue base, its sales base is far smaller. Its position is a single-asset concentration, and pipeline diversification is limited. The main comparison point for the sector is how FDA dialogue on statistical thresholds plays out.

06

Outlook

The most important event for the company is the final result of the FUEL-2 Phase 3 trial. A March 2026 press report pointed to a final result expected around the end of 2026, and that timing should be re-checked against later company disclosures.

In the seventh interim analysis released on March 16, 2026, the standard deviation of peak oxygen uptake, the primary endpoint, was 2.464, lower than the 2.490 disclosed at the December 2025 briefing.

A smaller standard deviation makes statistical significance easier to reach at the same effect size, which some observers read as a positive sign, but an interim figure does not guarantee the final result.

Expansion of ICD-10 code listings, which the company expects by the end of 2026, is the commercial groundwork it is building. On the funding side, the sixth unsecured private convertible bond issued in May 2026 totaled KRW 36.5 billion, and the proceeds are to fund operations including global clinical trials.

Overseas preparation for entry into Europe is proceeding separately from the FDA process. Whether the investment caution designation is lifted will depend on the audit report attached to the 2026 business report. The next checkpoints are therefore the operating loss and equity movements in the next periodic report.

07

Valuation

PER
—
PBR
42.5×
ROE
-70.4%
EPS
-₩985
BPS
₩1,561
Dividend per share
₩0

Mezzion's price-to-earnings ratio cannot be calculated because the last four quarters were loss-making.

On the book-value side, the price-to-book ratio sits in a range where the premium over net assets is very large, since total equity at end-2025 was only KRW 17.2 billion while the market value reflects pipeline expectations. The company pays no dividend, so its dividend yield sits below the industry average.

Over the multi-year period, operating losses have continued from 2022 onward, so earnings-based valuation metrics do not explain the stock well. The swing to profit in Q2 2026 lasted one quarter before a return to a loss in Q3, so a recovery in earnings is not yet established.

Valuation discussion therefore centers on company-value scenarios tied to the FUEL-2 result, and the gap between market value and total equity shows how large those expectations are. The Korea Exchange's investment caution designation is also a factor reflected in market assessment.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Trial redesign and improving statistics

FUEL-2 excludes super-Fontan patients from the start, which addresses a factor blamed for the failure of the first Phase 3 trial. The standard deviation in the March 2026 interim analysis was 2.464, below the 2.490 disclosed in December 2025.

The approval threshold agreed with the FDA is a p-value of 0.1 or below, a looser standard than the 0.05 used earlier.

Clinical data and coding groundwork

The company said that by early 2026 more than 4,000 patients and over 13,000 medical records had been accumulated. It expects many Fontan patients to be listed under the ICD-10 code by the end of 2026. Code listings would give clinical settings a defined basis for identifying eligible patients.

Revenue recovery through 2026

Revenue bottomed at KRW 2.02 billion in Q1 2026 and rose to KRW 2.2 billion in Q2 and KRW 2.42 billion in Q3, two consecutive quarterly increases. Q3 2026 revenue was up 13.7% from a year earlier. Net income attributable to controlling shareholders turned to a KRW 7.69 billion profit in Q2 2026.

09

Bear factors

Prior trial failure and approval delay

The first Phase 3 trial, FUEL-1, failed to achieve statistical significance, and the FDA declined approval in March 2022. The company has previously withdrawn an NDA voluntarily, so clinical uncertainty remains until the final FUEL-2 result is announced. A repeat of the earlier outcome would weigh on the company's overall valuation.

Thin equity and caution-stock designation

Press reports said total equity fell sharply from KRW 46.1 billion at end-2024 to KRW 17.2 billion at end-2025. By the end of March 2026, total equity was reported at about KRW 15.5 billion, close to paid-in capital of about KRW 15.2 billion.

The Korea Exchange designated the stock as an investment caution issue on March 17, 2026, and lifting that status depends on the audit result for the business year ending in 2026.

Convertible dilution and litigation

The sixth convertible bond issued in May 2026 totals KRW 36.5 billion. Press reports said the conversion prices of the fourth and fifth rounds sat below the then-current share price, and conversions became possible from June 20, 2026, raising concerns about share supply.

The company is also pursuing several civil lawsuits in the United States and Hong Kong, which adds to legal costs.

10

Risk factors

Clinical outcome risk

Because the company's value rests on udenafil alone, the FUEL-2 result is directly tied to the company's survival. If the final result, expected around late 2026 in press reports, is delayed or falls short, pipeline restructuring and further fundraising would become necessary. The trial redesign is a positive factor, but nothing is certain until the final statistics are confirmed.

Funding and dilution risk

The debt ratio stood at 470.1% at end-2025, and operating cash outflows continued every year from 2022 to 2025. As the KRW 36.5 billion CB issued in May 2026 converts into shares, the number of shares will rise and existing holdings will be diluted. Because the proceeds go to clinical operations, funding terms will shape the pace of the next trial stage.

Regulatory, exchange and litigation risk

The investment caution designation will be decided by the audit report for the 2026 business year. The FDA has previously required additional trials over statistical standards and design, so changes in regulatory positions could affect the timeline. Ongoing overseas civil lawsuits could add costs and reputational risk depending on their outcomes.

11

What to watch next

  1. End of December 2026

    Timing of the FUEL-2 final result and enrollment progress. The key question is whether the late-2026 timing cited in March 2026 press coverage is confirmed in company disclosures.

  2. By end-2026

    Scope of ICD-10 code listings. Whether the large number of Fontan patients the company expects are listed will serve as an indicator of commercial groundwork.

  3. End of March 2027 (2026 annual report filing deadline)

    Operating loss and equity figures in the 2026 annual report and the audit result. Whether the investment caution designation is lifted will be decided at this point.

  4. Ongoing from June 20, 2026

    Conversion requests under the fourth and fifth CB rounds and the use of sixth-round proceeds. These show the pace of share count growth and operating cash use.

12

Overall view

Mezzion's filed results show revenue peaking in 2023 and then declining, with operating losses continuing for four consecutive years through 2025.

In 2026, revenue rose for two consecutive quarters through Q3 and quarterly operating losses narrowed, but the net result attributable to controlling shareholders swung to profit in Q2 and back to a loss in Q3.

Total equity fell to KRW 17.2 billion at end-2025 and the debt ratio rose to 470.1%, and convertible bonds, including the KRW 36.5 billion round issued in May 2026, are being used as a main funding tool.

Positive factors include the trial design that excludes super-Fontan patients, the improved standard deviation in the interim analysis and the groundwork for ICD-10 coding. Negative factors include the history of trial setbacks, thin equity and the caution designation, and dilution from convertible bonds.

Because the company value leans heavily on the FUEL-2 result, the gap between reported earnings and expectations will persist until that result is known.

The next checkpoints are the timing of the FUEL-2 final result around late 2026, the operating loss and audit outcome in the 2026 annual report, and conversion volumes. This report is for information only and includes no buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. infoarounds.com
  2. mt.co.kr
  3. m.news.nate.com
  4. pinpointnews.co.kr
  5. businesspost.co.kr
  6. make2t.kr
  7. hankyung.com
  8. pharm.edaily.co.kr
  9. medipana.com
  10. medipana.com
  11. pharmnews.com
  12. pharm.edaily.co.kr
  13. pharm.edaily.co.kr
  14. sedaily.com
  15. news.nate.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis